Paul Heath: UK Approves Nuvaxovid COVID-19 Vaccine
Novavax’s COVID-19 vaccine, Nuvaxovid, has been authorised for use in the UK for those aged 18 and over. Prof. Paul Heath (St George’s, University of London, London, UK) kindly met with touchINFECTIOUS DISEASES to discuss the Novavax vaccine (Nuvaxovid), the clinical evidence in support of its use and the impact on the COVID-19 vaccination program in the UK.
More information on the phase 3 Novavax results, and the program of clinical trials across the US, South Africa and UK can be accessed below:
- Phase 3 results – Novavax investigational COVID-19 vaccine
- Novavax phase 3 program of clinical trials evaluating NVX-CoV2373 across the US, South Africa and UK
- Could you give us a brief overview of the Novavax vaccine, the clinical evidence in support of its use and the impact of the vaccine on the COVID-19 vaccination program in the UK?
Disclosures: Paul Heath has received grant/research support from Novavax, Pfizer, AstraZeneca, Valneva, and Moderna.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!